Gilder Gagnon Howe & CO LLC Aldeyra Therapeutics, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$4.41 - $6.12 $961,565 - $1.33 Million	-218,042 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$6.0 - $9.0 $3,564 - $5,346	-594 Reduced 0.27%	218,042 $1.31 Million
Q1 2019 May 17, 2019	BUY	$7.14 - $9.85 $10,631 - $14,666	1,489 Added 0.69%	218,636 $1.97 Million
Q4 2018 Feb 14, 2019	SELL	$7.26 - $13.29 $6,780 - $12,412	-934 Reduced 0.43%	217,147 $1.8 Million
Q3 2018 Oct 30, 2018	BUY	$6.8 - $14.35 $1.48 Million - $3.13 Million	218,081 New	218,081 $3.01 Million

118

36.3M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $302M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.